Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer
Year: 2024
Type: article
Abstract: Introduction Radiopharmaceutical Therapy (RPT) uses radioactive agents to target cancer at the cellular level Lu-177 targeting prostate-specific membrane antigen (PSMA), known as 177Lu- PSMA-617, can be used to treat metastatic, castration-resistant prostate cancer (mCRPC) 177Lu-PSMA-617 treatments use a standard dose and treatment regimen for all patients Patients exhibit different side effects and tumor response during treatment
Source: The Medicine Forum
Authors: Arturi, Frank J., Haldar, Nilanjan, Jain, Shray, Nguyen, Gia, Dinome, Jessie, Mourtada, Firas, Wilson, PhD, Lydia J.
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6986337053
FWCI:
Cites:
Cited by:
Related to: